June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
R9-SOCS1-KIR Peptide Abrogates Lipopolysaccharide Mediated Inflammation: Implications for the Treatment of Endotoxin Induced Uveitis
Author Affiliations & Notes
  • Chulbul M Ahmed
    Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida, United States
  • Anil P Patel
    Florida State University, Tallahassee, Florida, United States
  • Alfred S Lewin
    University of Florida, Gainesville, Florida, United States
  • Footnotes
    Commercial Relationships   Chulbul Ahmed, University of Florida (P); Anil Patel, None; Alfred Lewin, None
  • Footnotes
    Support  Unrestricted Grant from Research to Prevent Blindness; Shaler Richardson Professorship
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3451. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chulbul M Ahmed, Anil P Patel, Alfred S Lewin; R9-SOCS1-KIR Peptide Abrogates Lipopolysaccharide Mediated Inflammation: Implications for the Treatment of Endotoxin Induced Uveitis. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3451.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Suppressor of Cytokines Signaling 1 (SOCS1) is a cytoplasmic protein that limits the extent and duration of inflammatory response. We have shown that a cell penetrating peptide from the kinase inhibitory region (KIR) from SOCS1 (denoted as R9-SOCS1-KIR) can dampen the signaling emanating from JAK/STAT and TLR2/4 pathways. We have examined the ability of this peptide to counteract the inflammation caused by lipopolysaccharide (LPS), which is released during an infection or from leaching of intestinal microbiota.

Methods : R9-SOCS-KIR or its inactive control peptide were tested for anti-inflammatory properties in a mouse macrophage cell line, J774A.1, used as a surrogate for microglia and treated with LPS. Induction of inflammatory markers was tested by ELISA using the supernatants from treated cells, or Western blot analysis of treated cell extracts. Activation of inflammatory transcription factors was analyzed by following their nuclear translocation. ARPE-19 cells that were differentiated by growing for 4 weeks and treated with LPS with or without R9-SOCS1-KIR were used to evaluate the integrity of tight junction protein by immunostaining and by measurement of transepithelial electrical resistance (TEER).

Results : Treatment of J774A.1 cells with LPS resulted in secretion of NO and IL-1b, which was attenuated by R9-SOCS1-KIR. Induction of inflammatory markers, cyclooxygenase 2 (COX2) and iNOS observed in cells treated with LPS was suppressed when R9-SOCS1-KIR was simultaneously present. Treatment with LPS resulted in nuclear translocation of p65, the active subunit of NF-kB and the MAP kinase p38, both of which were prevented in the presence of R9-SOCS1-KIR. Uniform distribution of Zona occludens 1 (ZO-1) along the cell membrane was disrupted and TEER reduced by treatment with LPS, both of which were prevented by R9-SOCS1-KIR.

Conclusions : Protection against inflammatory insults afforded by R9-SOCS1-KIR in a macrophage cell line and a cell line from retinal pigment epithelium suggests that it has therapeutic potential against inflammatory ocular disorders, including infection induced uveitis.

This is a 2021 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.